HDAC9 and Miyoshi myopathy: Having demonstrated its pan-HDAC inhibitory activity, and taking into account the promising clinical data which emerged from MM patients treated with proteasome inhibitors and pan-HDACi combination therapies, we also explored whether oleacein could enhance the anti-tumor activity of bortezomib or carfilzomib.